Document is current
Any future updates will be listed below
-
Authors
Alvarenga, José Miguel https://orcid.org/0000-0003-2552-9333
Bieber, Thomas https://orcid.org/0000-0002-8800-3817
Torres, Tiago https://orcid.org/0000-0003-0404-0870
-
Funding
Funding for this research was provided by:
Universidade do Porto
- License Information
-
More Information
Article History
Accepted: 9 September 2024
First Online: 4 October 2024
Declarations
:
: Open access funding provided by FCT|FCCN (b-on). No funding has been received for the preparation of this manuscript.
: José Miguel Alvarenga has no conflicts of interest. Thomas Bieber was speaker and/or consultant and/or investigator for AbbVie, Affibody, Almirall, AnaptysBio, Arena, Asana Biosciences, ASLAN pharma, Bayer Health, BioVerSys, Boehringer Ingelheim, Bristol-Myers Squibb, Connect Pharma, Dermavant, DIECE Therapeutics, Domain Therapeutics, EQRx, Galderma, Glenmark, GSK, Incyte, Innovaderm, IQVIA, Janssen, Kirin, Kymab, LEO, LG Chem, Lilly, L’Oréal, MSD, Novartis, Numab, OM-Pharma, Pfizer, Pierre Fabre, Q32bio, RAPT, Sanofi/Regeneron, and UCB. He is founder and chairman of the board of the non-profit biotech “Davos Biosciences.” Tiago Torres has received consultancy and/or speaker’s honoraria from and/or participated in clinical trials sponsored by AbbVie, Amgen, Almirall, Arena Pharmaceuticals, Biocad, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Fresenius-Kabi, Janssen, LEO Pharma, Eli Lilly, MSD, Mylan, Novartis, Pfizer, Samsung-Bioepis, Sanofi-Genzyme, Sandoz, and UCB.
: JMA, TB, and TT had the idea for the article, performed the literature search and data analysis, and drafted and critically revised the work.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
